Opioids

Discussions Files Images Videos Links Events Knowledge Share All

Source: Austin EJ, Chen J, Briggs ES, et al. Integrating Opioid Use Disorder Treatment Into Primary Care Settings. JAMA Netw Open. 2023;6(8):e2328627. doi:10.1001/jamanetworkopen.2023.28627 Key Points Question What are multidisciplinary primary care team perspectives on barriers and facilitators to...

Integrating Opioid Use Disorder Treatment Into Primary Care Settings_1.pdf

June 21, 2023 Presenter: Jim Caruso, M.D., Chief Medical Examiner/Coroner, City and County of Denver

Fentanyl and Public Health Jim Caruso Denver.pdf

Presentación realizada por Lucía Hipólito el 21 de junio del 2023

Lucía Hipolito fentanilo 21 junio 2023.pdf

Presentación realizada por Marya Hynes el 21 de junio del 2023

Marya Hynes fentanilo 21 junio 2023.pdf

Presentation by Marya Hynes June 21, 2023

Marya Hynes fentanyl June 21 2023.pdf

Source: Chhatwal J, Mueller PP, Chen Q, et al. Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States. JAMA Netw Open. 2023;6(6):e2314925. doi:10.1001/jamanetworkopen.2023.14925 Key Points Question What is the association of sustaining public...

Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States.pdf

Fuente: https://nida.nih.gov/es/download/20630/el-fentanilo-drugfacts.pdf El fentanilo es un fuerte opioide sintético similar a la morfina, pero entre 50 y 100 veces más potente. Es un fármaco recetado que a veces también se usa en forma ilegal. Al igual que la morfina, por lo general se receta a...

El fentanilo, información de NIDA.pdf

Source: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services. Fentanyl is a powerful synthetic opioid that is similar to morphine but is 50 to 100 times more potent. It is a prescription drug that is also made and used illegally. Like morphine...

fentanyl drugfacts NIDA.pdf

Source: Snowdon, J., & Choi, N. (2022). Unanticipated Changes in Drug Overdose Death Rates in Canada During the Opioid Crisis. International journal of mental health and addiction, 1–19. Advance online publication. https://doi.org/10.1007/s11469-022-00932-9

Unanticipated Changes in Drug Overdose Death Rates in Canada During the Opioid Crisis_0.pdf

Source: Marel, C., Wilson, J., Darke, S., Ross, J., Slade, T., Haber, P. S., Haasnoot, K., Visontay, R., Keaveny, M., Tremonti, C., Mills, K. L., & Teesson, M. (2023). Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the...

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence - Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS)_1.pdf

Fuente: https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-una-nueva-opcion-de-tratamiento-con-buprenorfina-para-el-trastorno-por-consumo-de

Para publicación inmediata: 24 de mayo del 2023

Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi (buprenorfina) de liberación prolongada para tratar el trastorno por consumo de opioides (OUD, por sus siglas en inglés) de moderado a grave. Brixadi está disponible en dos formulaciones, una inyección semanal...

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder

For Immediate Release: May 23, 2023

Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and...

Source: https://store.samhsa.gov/sites/default/files/pep23-02-01-002.pdf This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of...

Advisory Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder_1.pdf

Upcoming Events

There aren't any upcoming events

All Events

Integrating Opioid Use Disorder Treatment Into Primary Care Settings

Webinar “Fentanilo: Un Problema Actual”

Fentanyl Overdoses and Their Public Health Consequences

Farmacología de los analgésicos opioides

El Fentanilo en las Américas: un problema actual

Fentanyl in the Americas: A Current Problem

Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States

El fentanilo, información de NIDA

Fentanyl DrugFacts

Unanticipated Changes in Drug Overdose Death Rates in Canada During the Opioid Crisis.

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS).

La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder

Upcoming Events